ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,532.30
0.45%
S&P ASX All Technology
3,983.90
1.06%
Brent Oil
76.385
0.00%
US Dollar vs AUD
1.60334
0.00%
Bitcoin
102,344.03
-0.07%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Replimune Group Inc (REPL)

  7. Replimune Group Inc (REPL) News

REPL

Replimune (REPL)

Replimune Group Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REPL
DateTimeSourceHeadlineSymbolCompany
23/01/202509:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
22/01/202500:00GlobeNewswire Inc.Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced MelanomaNASDAQ:REPLReplimune Group Inc
18/01/202509:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
11/01/202508:01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
09/01/202500:00GlobeNewswire Inc.Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical TrialsNASDAQ:REPLReplimune Group Inc
24/12/202400:00GlobeNewswire Inc.Replimune to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:REPLReplimune Group Inc
21/12/202409:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
19/12/202413:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
17/12/202408:48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REPLReplimune Group Inc
05/12/202400:30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:REPLReplimune Group Inc
28/11/202400:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
27/11/202409:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:REPLReplimune Group Inc
27/11/202400:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
26/11/202415:55GlobeNewswire Inc.Replimune Announces Pricing of Upsized Public OfferingNASDAQ:REPLReplimune Group Inc
25/11/202423:09GlobeNewswire Inc.Replimune Announces Proposed Public OfferingNASDAQ:REPLReplimune Group Inc
22/11/202409:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REPLReplimune Group Inc
22/11/202408:05GlobeNewswire Inc.Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval PathwayNASDAQ:REPLReplimune Group Inc
21/11/202413:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
21/11/202413:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REPLReplimune Group Inc
20/11/202409:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
14/11/202423:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:REPLReplimune Group Inc
13/11/202400:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REPLReplimune Group Inc
13/11/202400:00GlobeNewswire Inc.Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate UpdateNASDAQ:REPLReplimune Group Inc
10/11/202405:00GlobeNewswire Inc.Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)NASDAQ:REPLReplimune Group Inc
09/11/202408:01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
31/10/202400:15GlobeNewswire Inc.Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:REPLReplimune Group Inc
17/10/202408:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:REPLReplimune Group Inc
10/10/202407:01GlobeNewswire Inc.Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:REPLReplimune Group Inc
01/10/202422:00GlobeNewswire Inc.Replimune to Present at Two Upcoming Investor ConferencesNASDAQ:REPLReplimune Group Inc
15/09/202423:45GlobeNewswire Inc.Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024NASDAQ:REPLReplimune Group Inc
 Showing the most relevant articles for your search:NASDAQ:REPL

Your Recent History

TSXV
CIN
Canadian International Minerals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads